<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01447914</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-03470</org_study_id>
    <secondary_id>NCI-2011-03470</secondary_id>
    <secondary_id>CDR0000712984</secondary_id>
    <secondary_id>2011-0197</secondary_id>
    <secondary_id>8984</secondary_id>
    <secondary_id>U01CA062461</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>N01CM00039</secondary_id>
    <nct_id>NCT01447914</nct_id>
  </id_info>
  <brief_title>Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase II Study of the c-Met Inhibitor ARQ 197 in Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and how well tivantinib works in treating
      patients with relapsed, or relapsed and refractory multiple myeloma. Tivantinib may stop the
      growth of cancer cells by blocking some of the enzymes needed for cell growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the overall response rate of patients with relapsed, or relapsed and
      refractory multiple myeloma treated with the c-Met inhibitor ARQ 197 (tivantinib) as a single
      agent.

      II. To define the toxicities of single agent ARQ 197 in a population of patients with
      relapsed, or relapsed and refractory multiple myeloma.

      SECONDARY OBJECTIVES:

      I. To obtain preliminary evidence of the durability of responses to single agent ARQ 197,
      including the progression free survival (PFS), the duration of response (DOR), and the time
      to next treatment (TTNT).

      II. To correlate the activation status of the hepatocyte growth factor (HGF)/c-Met pathway in
      primary myeloma cells at baseline, as defined by gene expression profiling and reverse phase
      protein array data, with the above measures of efficacy of ARQ 197.

      III. To correlate serum and marrow HGF, HGF activator (HGFA), and soluble c-Met (sc-Met)
      levels with the activation status of the HGF/c-Met pathway in primary myeloma cells at
      baseline, and with the above measures of efficacy of ARQ 197.

      TERTIARY OBJECTIVES:

      I. To evaluate the symptom burden of relapsed, or relapsed and refractory multiple myeloma
      patients undergoing therapy with single agent ARQ 197 using the M. D. Anderson Symptom
      Inventory (MDASI) and its multiple myeloma module (MDASI-MM) II. To evaluate the impact of
      therapy with single agent ARQ 197 for relapsed, or relapsed and refractory multiple myeloma
      on patient reported outcomes using the European Organization for Research on the Treatment of
      Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30 (QLQ-C30), and the
      myeloma-specific module QLQ-MY20.

      III. To evaluate the impact of therapy with single agent ARQ 197 for relapsed, or relapsed
      and refractory multiple myeloma on the ability to collect stem cells in any patients who go
      on to undergo subsequent stem cell mobilization.

      OUTLINE:

      Patients receive tivantinib orally (PO) twice daily (BID) on days 1-28. Courses continue
      every 28 days in the absence of disease progression or unacceptable toxicity. Patients
      undergo blood, urine, and bone marrow collection for gene expression profile, proteomic
      profiling, and other correlative studies. Patients may complete the MDASI and its MDASI-MM,
      the EORTC QLQ-C30, and the myeloma-specific module QLQMY20 questionnaires at baseline and
      periodically during study.

      After completion of study treatment, patients are followed up for 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>ORR using International Myeloma Working Group Response Criteria, achieve at least a partial response (PR) or better: Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR): CR: Negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and &lt;5% plasma cells in bone marrow; sCR: CR+Normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; PR: ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90%; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level &lt;100mg per 24 hour; Stable Disease (SD): Not CR, VGPR, PR or progressive disease; Progressive Disease (PD):&gt;25% from lowest value Serum and/or Urine M-component, new lesions or soft tissue plasmacytomas, or hypercalcemia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicities of Single Agent Tivantinib: Grade 3 Nonhematologic or Grade 4 Hematologic Toxicities According to the Common Terminology Criteria for Adverse Events (CTCAE), Version 4</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Toxicities with a grade 3 nonhematologic or grade 4 hematologic toxicities according to CTCAE, version 4. Grade 3 and estimated with a 95% credible interval. Summary statistics will be provided for continuous variables.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>From start of the treatment to disease progression or death (regardless of cause of death), whichever comes first, assessed up to 30 days</time_frame>
    <description>Kaplan and Meier product limit methods will be used to estimate the median PFS with 95% confidence intervals. Furthermore, the univariate and multivariate Cox proportional hazards regression model will be used to identify prognostic factors for PFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From first observation of partial response to the time of disease progression, assessed up to 30 days</time_frame>
    <description>Kaplan and Meier product limit methods will be used to estimate the DOR with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Treatment (TTNT)</measure>
    <time_frame>From registration on trial to next treatment or death due to any cause, whichever comes first, assessed up to 30 days</time_frame>
    <description>Kaplan and Meier product limit methods will be used to estimate the TTNT with 95% confidence intervals.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>ARQ 197 Treatment (Tivantinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Tivantinib 360 mg twice daily continuously for each day (days 1-28) of every 4-week treatment cycle (taken as three tablets of 120 mg each). Courses continue every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tivantinib</intervention_name>
    <description>Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.</description>
    <arm_group_label>ARQ 197 Treatment (Tivantinib)</arm_group_label>
    <other_name>ARQ 197</other_name>
    <other_name>c-Met Inhibitor ARQ 197</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diagnostic laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>ARQ 197 Treatment (Tivantinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>ARQ 197 Treatment (Tivantinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>ARQ 197 Treatment (Tivantinib)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have been previously diagnosed with histologically or cytologically
             confirmed symptomatic multiple myeloma, which requires the presence of all three of
             the following International Myeloma Working Group criteria, except as noted:

               -  Clonal bone marrow plasma cells &gt;= 10%

               -  A monoclonal protein in either serum or urine

               -  Evidence of end-organ damage that can be attributed to the underlying plasma cell
                  proliferative disorder (to include one of the following):

                    -  Hypercalcemia (corrected calcium &gt; 2.75 mmol/L or 11.5 mg/dL)

                    -  Renal insufficiency attributable to myeloma (serum creatinine &gt; 1.9 mg/dL)

                    -  Anemia; normochromic, normocytic with a hemoglobin value &gt;= 2 g/dL below the
                       lower limit of normal, or a hemoglobin or &lt; 10 g/dL

                    -  Bone lytic lesions, severe osteopenia, or pathologic fractures

                    -  Patients with a biopsy-proven plasmacytoma and either a serum or urine
                       monoclonal protein will also be considered to have met the diagnostic
                       criteria for multiple myeloma in the absence of clonal marrow plasmacytosis
                       of &gt;= 10%

          -  Patients must have measurable disease, as defined by at least one of the following:

               -  Serum monoclonal protein level &gt;= 0.5 g/dL for immunoglobulin (Ig)G, IgA, or IgM
                  disease

               -  Monoclonal protein or total serum IgD &gt;= 0.5 g/dL for IgD disease

               -  Urinary M-protein excretion of &gt;= 200 mg over a 24-hour period

               -  Involved free light chain level &gt;= 10 mg/dL, along with an abnormal free light
                  chain ratio

          -  Patients must have had at least one, but not more than four prior lines of therapy for
             their disease, with lines of therapy being separated by the presence of documented
             disease progression; using this definition, treatment with induction therapy, followed
             by high-dose chemotherapy and autologous stem cell transplantation, and finally by
             maintenance therapy, would constitute one line, provided that multiple myeloma did not
             meet criteria for progression at any time during this period

          -  Patients with relapsed disease will be considered to be those who have had
             progression, as defined above, off of any therapy, and who completed their therapy
             more than 60 days prior to the finding of progression; patients with relapsed and
             refractory disease will be considered to be those who have had progression, as defined
             above, while still on their last line of therapy, or who progressed within 60 days of
             finishing their most recent therapy

          -  Patients must have completed their most recent drug therapy directed at multiple
             myeloma in the following time frames:

               -  Chemotherapy, biological therapy, immunotherapy, or an investigational therapy at
                  least 3 weeks prior to starting c-Met inhibitor ARQ197

               -  Corticosteroids at least 3 weeks prior to starting ARQ 197, except for a dose
                  equivalent to dexamethasone of no greater than 4 mg/day

               -  Nitrosoureas, nitrogen mustards, mitomycin C, or monoclonal antibodies at least 6
                  weeks prior to starting ARQ 197

               -  Autologous stem cell transplantation at least 12 weeks prior to starting ARQ 197

               -  Allogeneic stem cell transplantation at least 24 weeks prior to starting ARQ 197,
                  and these patients must also not have moderate to severe active acute or chronic
                  graft-versus-host disease

          -  Patients must be willing and able to provide voluntary written informed consent, with
             the understanding that consent may be withdrawn by the subject at any time without
             prejudice to their future medical care

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 (Karnofsky
             &gt;= 60%)

          -  Absolute neutrophil count (ANC) &gt;= 1,000 cells/mm^3 without growth factors within 1
             week of the initiation of treatment

          -  Total white blood cell count (WBC) &gt;= 2,000 cells/mm^3 without growth factors within 1
             week of the initiation of treatment

          -  Hemoglobin &gt;= 8 g/dL without red blood cell transfusions within 2 weeks of the
             initiation of treatment

          -  Platelet counts of &gt;= 100,000 cells/mm^3 for patients who have bone marrow
             plasmacytosis of &lt; 50%, or &gt;= 50,000 cells/mm^3 for patients who have bone marrow
             plasmacytosis of &gt;= 50%

          -  Total bilirubin =&lt; 1.5 times the upper limit of the institutional normal (ULN) values

          -  Total aspartate aminotransferase (AST) (serum glutamic oxaloacetic acid transaminase
             [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase
             [SGPT]) =&lt; 2.5 times ULN values

          -  Serum creatinine within the institutional normal limits OR if the creatinine is
             elevated, creatinine clearance (CrCl) &gt;= 30 mL/min., as measured by a 24-hour urine
             collection, or estimated by the Cockcroft and Gault formula

          -  Patients must have evidence of adequate cardiac function, as defined by the following:

               -  Absence of New York Heart Association (NYHA) class II, III, or IV congestive
                  heart failure

               -  Absence of uncontrolled angina or hypertension

               -  Absence of myocardial infarction in the previous 6 months

               -  Absence of clinically significant bradycardia or other uncontrolled cardiac
                  arrhythmia defined as grade 3 or 4 according to National Cancer Institute (NCI)
                  Common Terminology Criteria for Adverse Events (CTCAE), version 4.0

          -  Patients who have received radiation therapy must have completed this at least 4 weeks
             prior to starting therapy with ARQ 197, with the following exceptions:

               -  Local radiation therapy to enhance bone healing of a pathologic fracture may have
                  been performed, as long as it was completed at least 2 weeks prior to starting
                  ARQ 197

               -  Local radiation therapy to treat post-fracture pain that is refractory to
                  analgesics may have been performed, as long as it was completed at least 2 weeks
                  prior to starting ARQ197

          -  Patients who have undergone any recent major surgery must have done so at least 4
             weeks prior to starting therapy with ARQ 197, with the following exceptions:

               -  Vertebroplasty and/or kyphoplasty, which must have been performed at least 1 week
                  prior to starting ARQ 197

               -  Planned elective surgery unrelated to the patient's diagnosis of multiple
                  myeloma, such as hernia repair, may be allowed, at the discretion of the
                  Principal Investigator, as long as it was performed at least 2 weeks prior to
                  starting ARQ 197, and patients have recovered fully from this procedure

          -  Human immunodeficiency virus (HIV)-seropositive patients with acceptable organ
             function who meet the patient selection criteria, and who are not on combination
             antiretroviral therapy, and whose absolute CD4+ count is &gt;= 400 cells per cubic
             millimeter of blood, will be eligible; however, HIV positive patients on combination
             antiretroviral therapy will be ineligible

          -  Male patients must agree to use an adequate method of contraception for the duration
             of the study since the effects of ARQ 197 on the developing human fetus are unknown;
             female patients must be either post- menopausal, free from menses for &gt;= 2 years,
             surgically sterilized, or willing to use two adequate barrier methods of contraception
             to prevent pregnancy, or must agree to abstain from heterosexual activity throughout
             the study; female patients of childbearing potential must have a negative serum
             (beta-human chorionic gonadotropin [beta-HCG]) or urine pregnancy test before
             receiving the first dose of ARQ 197; should a woman become pregnant or suspect she is
             pregnant while she or her partner is participating in this study, she should inform
             her treating physician immediately

        Exclusion Criteria:

          -  Patients who are receiving any concurrent investigational agent with known or
             suspected activity against multiple myeloma, or those whose adverse events due to
             agents administered more than 4 weeks earlier have not recovered to a severity of
             grade 0 or grade 1

          -  Patients who have known central nervous system involvement with multiple myeloma will
             be excluded from this clinical trial

          -  Patients who have previously been treated with another agent targeting the HGF/c-Met
             axis, including either monoclonal antibodies to HGF or c-Met, or small molecule
             inhibitors of c-Met

          -  Patients with a known history of allergic reactions attributed to compounds of similar
             chemical or biologic composition to ARQ 197

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements, in the opinion of the Principal Investigator

          -  Pregnant or lactating women are excluded from this study

          -  HIV positive patients on combination antiretroviral therapy are ineligible because of
             the potential for pharmacokinetic interactions with ARQ 197; however, HIV seropositive
             patients with acceptable organ function who meet the patient selection criteria, and
             who are not on combination antiretroviral therapy, will be eligible

          -  Patients with non-secretory multiple myeloma, active plasma cell leukemia, defined as
             either having 20% of peripheral white blood cells comprised of CD138+ plasma cells, or
             an absolute plasma cell count of 2 x 10^9/L, known amyloidosis, or known POEMS
             syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy,
             monoclonal protein, and skin changes)

          -  Patients who have required plasmapheresis and exchange less than 2 weeks prior to
             initiation of therapy with ARQ 197

          -  Patients with known active hepatitis A, B, and/or C infection

          -  Patients with a &quot;currently active&quot; second malignancy, other than non-melanoma skin
             cancer and carcinoma in situ of the cervix, should not be enrolled; patients are not
             considered to have a &quot;currently active&quot; malignancy if they have completed therapy for
             a prior malignancy, are disease free from prior malignancies for &gt; 5 years, and are
             considered by their physician to be at less than 30% risk of relapse; in addition,
             patients with basal cell carcinoma of the skin, superficial carcinoma of the bladder,
             carcinoma of the prostate with a current prostate-specific antigen (PSA) value of &lt;
             0.5 ng/mL, or cervical intraepithelial neoplasia will be eligible; finally, patients
             who are on hormonal therapy for a history of either prostate cancer or breast cancer
             may enroll, provided that there has been no evidence of disease progression during the
             previous three years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Orlowski</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Official Website</description>
  </link>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2011</study_first_posted>
  <results_first_submitted>January 26, 2015</results_first_submitted>
  <results_first_submitted_qc>March 12, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 13, 2015</results_first_posted>
  <last_update_submitted>March 12, 2015</last_update_submitted>
  <last_update_submitted_qc>March 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>c-Met Inhibitor ARQ-197</keyword>
  <keyword>tivantinib</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>plasma cell proliferative disorder</keyword>
  <keyword>Hypercalcemia</keyword>
  <keyword>hematologic malignancy</keyword>
  <keyword>plasma cell dyscrasia</keyword>
  <keyword>cast nephropathy</keyword>
  <keyword>amyloidosis</keyword>
  <keyword>osteolysis</keyword>
  <keyword>Renal insufficiency</keyword>
  <keyword>Anemia</keyword>
  <keyword>Bone lytic lesions</keyword>
  <keyword>severe osteopenia</keyword>
  <keyword>pathologic fractures</keyword>
  <keyword>biopsy-proven plasmacytoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Total Recruitment Period: November 30, 2011 to August 1, 2013. All recruitment done at University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tivantinib Treatment</title>
          <description>Oral Tivantinib 360 mg twice daily continuously for each day of every 28 day treatment cycle (taken as three tablets of 120 mg each)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tivantinib Treatment</title>
          <description>Oral Tivantinib 360 mg twice daily continuously for each day of every 28 day treatment cycle (taken as three tablets of 120 mg each)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" lower_limit="49" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Stem Cell Transplantation (SCT)</title>
          <description>Number of participants who had or did not have SCT procedures prior beginning study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Prior SCT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Prior SCT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>ORR using International Myeloma Working Group Response Criteria, achieve at least a partial response (PR) or better: Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR): CR: Negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and &lt;5% plasma cells in bone marrow; sCR: CR+Normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; PR: ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90%; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level &lt;100mg per 24 hour; Stable Disease (SD): Not CR, VGPR, PR or progressive disease; Progressive Disease (PD):&gt;25% from lowest value Serum and/or Urine M-component, new lesions or soft tissue plasmacytomas, or hypercalcemia.</description>
        <time_frame>Up to 30 days</time_frame>
        <population>Proportion of participants reported on an intent-to-treat basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Tivantinib Treatment</title>
            <description>Oral Tivantinib 360 mg twice daily continuously for each day of every 28 day treatment cycle (taken as three tablets of 120 mg each)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>ORR using International Myeloma Working Group Response Criteria, achieve at least a partial response (PR) or better: Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR) or Partial Response (PR): CR: Negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and &lt;5% plasma cells in bone marrow; sCR: CR+Normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; PR: ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90%; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level &lt;100mg per 24 hour; Stable Disease (SD): Not CR, VGPR, PR or progressive disease; Progressive Disease (PD):&gt;25% from lowest value Serum and/or Urine M-component, new lesions or soft tissue plasmacytomas, or hypercalcemia.</description>
          <population>Proportion of participants reported on an intent-to-treat basis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Toxicities of Single Agent Tivantinib: Grade 3 Nonhematologic or Grade 4 Hematologic Toxicities According to the Common Terminology Criteria for Adverse Events (CTCAE), Version 4</title>
        <description>Toxicities with a grade 3 nonhematologic or grade 4 hematologic toxicities according to CTCAE, version 4. Grade 3 and estimated with a 95% credible interval. Summary statistics will be provided for continuous variables.</description>
        <time_frame>Up to 30 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Kaplan and Meier product limit methods will be used to estimate the median PFS with 95% confidence intervals. Furthermore, the univariate and multivariate Cox proportional hazards regression model will be used to identify prognostic factors for PFS.</description>
        <time_frame>From start of the treatment to disease progression or death (regardless of cause of death), whichever comes first, assessed up to 30 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Kaplan and Meier product limit methods will be used to estimate the DOR with 95% confidence intervals.</description>
        <time_frame>From first observation of partial response to the time of disease progression, assessed up to 30 days</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Next Treatment (TTNT)</title>
        <description>Kaplan and Meier product limit methods will be used to estimate the TTNT with 95% confidence intervals.</description>
        <time_frame>From registration on trial to next treatment or death due to any cause, whichever comes first, assessed up to 30 days</time_frame>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Cycles of Tivantinib Treatment Administered</title>
        <description>Number of treatment cycles completed by study participants.</description>
        <time_frame>From start of participant treatment to completion or disease progression; Data collected for overall study period January 2012 to February 2014.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tivantinib Treatment</title>
            <description>Oral Tivantinib 360 mg twice daily continuously for each day of every 28 day treatment cycle (taken as three tablets of 120 mg each)</description>
          </group>
        </group_list>
        <measure>
          <title>Cycles of Tivantinib Treatment Administered</title>
          <description>Number of treatment cycles completed by study participants.</description>
          <units>number of treatment cycles</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected till 30 days of the last dose of the investigational agent and include all who receive any amount of study drug. Overall collection period January 2012 to February 2014.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tivantinib Treatment</title>
          <description>Oral Tivantinib 360 mg twice daily continuously for each day of every 28 day treatment cycle (taken as three tablets of 120 mg each)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia (Neutrophil count decreased)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteremia Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Anorectal Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Multiple pulmonary emboli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hyperlipidemia</sub_title>
                <description>Note: Baseline collection.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diabetes</sub_title>
                <description>Note: Baseline collection.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Watering eyes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diverticulitis flare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gait distrubance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Muscle Discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Urinary tract pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Postnasal Drip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Orlowski, MD, PhD / Professor, Department of Lymphoma/Myeloma</name_or_title>
      <organization>University of Texas (UT) MD Anderson Cancer Center</organization>
      <phone>713-792-2860</phone>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

